EP300 and Thrombocytopenia: Notably, unlike the thrombocytopenia exhibited by p300/CBP BRDi or BET inhibitors46,47, CBPD-409 did not affect platelets in CD1 mice (Figure 7E), which was further confirmed by bone marrow H&E staining showing that CBPD-409 did not affect megakaryocytes48 (Figure 7F).